Logo image of CMRA

COMERA LIFE SCIENCES HOLDING (CMRA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CMRA - US20037C1080 - Common Stock

0.2227 USD
-0.02 (-8.88%)
Last: 11/16/2023, 8:21:40 PM
0.09 USD
-0.13 (-59.59%)
After Hours: 11/16/2023, 8:21:40 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CMRA. CMRA was compared to 533 industry peers in the Biotechnology industry. CMRA may be in some trouble as it scores bad on both profitability and health. CMRA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CMRA has reported negative net income.
CMRA had a negative operating cash flow in the past year.
CMRA Yearly Net Income VS EBIT VS OCF VS FCFCMRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 -5M -10M -15M

1.2 Ratios

CMRA has a Return On Assets of -439.19%. This is amonst the worse of the industry: CMRA underperforms 98.00% of its industry peers.
Industry RankSector Rank
ROA -439.19%
ROE N/A
ROIC N/A
ROA(3y)-318.65%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CMRA Yearly ROA, ROE, ROICCMRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 0 500 -500 1K -1K

1.3 Margins

CMRA has a Gross Margin of 74.17%. This is amongst the best in the industry. CMRA outperforms 84.17% of its industry peers.
CMRA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMRA Yearly Profit, Operating, Gross MarginsCMRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 0 -500 -1K -1.5K -2K -2.5K

More info and screens

1

2. Health

2.1 Basic Checks

CMRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
CMRA has less shares outstanding than it did 1 year ago.
CMRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CMRA Yearly Shares OutstandingCMRA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 5M 10M 15M
CMRA Yearly Total Debt VS Total AssetsCMRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2M 4M 6M

2.2 Solvency

Based on the Altman-Z score of -36.24, we must say that CMRA is in the distress zone and has some risk of bankruptcy.
CMRA has a Altman-Z score of -36.24. This is amonst the worse of the industry: CMRA underperforms 95.00% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -36.24
ROIC/WACCN/A
WACC11.01%
CMRA Yearly LT Debt VS Equity VS FCFCMRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 0 5M -5M

2.3 Liquidity

CMRA has a Current Ratio of 0.46. This is a bad value and indicates that CMRA is not financially healthy enough and could expect problems in meeting its short term obligations.
CMRA has a worse Current ratio (0.46) than 95.50% of its industry peers.
A Quick Ratio of 0.46 indicates that CMRA may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.46, CMRA is doing worse than 95.17% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.46
Quick Ratio 0.46
CMRA Yearly Current Assets VS Current LiabilitesCMRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2M 4M 6M

More info and screens

1

3. Growth

3.1 Past

CMRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.05%, which is quite good.
The Revenue has grown by 95.59% in the past year. This is a very strong growth!
EPS 1Y (TTM)13.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.93%
Revenue 1Y (TTM)95.59%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%114.72%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CMRA Yearly Revenue VS EstimatesCMRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 200K 400K 600K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CMRA. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMRA Price Earnings VS Forward Price EarningsCMRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMRA Per share dataCMRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CMRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COMERA LIFE SCIENCES HOLDING

NASDAQ:CMRA (11/16/2023, 8:21:40 PM)

After market: 0.09 -0.13 (-59.59%)

0.2227

-0.02 (-8.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2022-11-10/bmo
Earnings (Next)N/A N/A
Inst Owners1.03%
Inst Owner Change0%
Ins Owners46.33%
Ins Owner Change0%
Market Cap6.85M
Revenue(TTM)1.10M
Net Income(TTM)-10.28M
AnalystsN/A
Price TargetN/A
Short Float %0.04%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.23
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.59
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0.04
BVpS-0.05
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -439.19%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.17%
FCFM N/A
ROA(3y)-318.65%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 118.39%
Cap/Sales 10.84%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.46
Quick Ratio 0.46
Altman-Z -36.24
F-Score4
WACC11.01%
ROIC/WACCN/A
Cap/Depr(3y)69.7%
Cap/Depr(5y)N/A
Cap/Sales(3y)17.24%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.93%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)95.59%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%114.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y21.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-151.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-160.03%
OCF growth 3YN/A
OCF growth 5YN/A

COMERA LIFE SCIENCES HOLDING / CMRA FAQ

Can you provide the ChartMill fundamental rating for COMERA LIFE SCIENCES HOLDING?

ChartMill assigns a fundamental rating of 1 / 10 to CMRA.


Can you provide the valuation status for COMERA LIFE SCIENCES HOLDING?

ChartMill assigns a valuation rating of 0 / 10 to COMERA LIFE SCIENCES HOLDING (CMRA). This can be considered as Overvalued.


Can you provide the profitability details for COMERA LIFE SCIENCES HOLDING?

COMERA LIFE SCIENCES HOLDING (CMRA) has a profitability rating of 1 / 10.